早期去甲肾上腺素给药与钝性创伤失血性休克患者24小时死亡率的关联
该回顾性、多中心、观察性队列研究纳入美国与法国3个登记库2013年1月1日至2018年12月31日连续钝性创伤合并失血性休克(院前或入院收缩压<100 mm Hg且有出血证据)且入院存活的患者2164例,其中1498例(69.2%)在出血控制前接受去甲肾上腺素持续给药。采用Rubin因果模型、倾向评分逆概率加权及双重稳健方法共5种分析策略估计平均治疗效应,5种策略均未显示去甲肾上腺素与24小时死亡率(ATE范围-4.6,95%CI -11.9至2.7,至2.1,95%CI -2.1至6.3)或院内死亡率(ATE范围-1.3,95%CI -9.5至6.9,至5.3,95%CI -2.1至12.8)存在统计学显著关联。作者认为需随机临床试验进一步评估去甲肾上腺素对失血性休克患者是否安全。
要点
- 钝性创伤失血性休克且入院存活患者中,69.2%(1498/2164)在出血控制前接受去甲肾上腺素持续给药。
- 5种分析策略均未显示早期去甲肾上腺素与24小时死亡率存在统计学显著关联,ATE范围-4.6(95%CI -11.9至2.7)至2.1(95%CI -2.1至6.3)。
- 早期去甲肾上腺素与院内死亡率同样无统计学显著关联,ATE范围-1.3(95%CI -9.5至6.9)至5.3(95%CI -2.1至12.8)。
- 研究人群24小时死亡率为17.8%(385/2164),院内死亡率为35.6%(770/2164)。
- 作者认为需随机临床试验研究早期去甲肾上腺素对创伤低血压患者的作用,以进一步评估其用于失血性休克是否安全。
适用人群与场景
- 美国与法国3个登记库中2013年1月1日至2018年12月31日连续纳入的钝性创伤患者,入院时存活且合并失血性休克。
- 失血性休克定义为院前或入院收缩压低于100 mm Hg,并有出血证据:院前或复苏室输注浓缩红细胞、接受紧急止血治疗、最初24小时内输注超过10单位浓缩红细胞或死于出血。
- 钝性创伤定义为任何暴露于非穿透性动能、碰撞或减速。
诊断标准与关键阈值
- 失血性休克:院前或入院收缩压低于100 mm Hg,且具备出血证据(院前或复苏室输注浓缩红细胞、接受紧急止血治疗、最初24小时内输注超过10单位浓缩红细胞或死于出血)。
- 钝性创伤:任何暴露于非穿透性动能、碰撞或减速。
处置流程与药物剂量
- 暴露为在院前环境或复苏室、出血控制之前,按欧洲指南持续给予去甲肾上腺素。
- 1497例(69.1%)需要紧急出血控制,128例(5.9%)接受院前浓缩红细胞输注,543例(25.0%)接受大量输血。
研究设计与关键结果
- 研究类型为回顾性、多中心、观察性队列研究,使用美国与法国3个登记库数据;共筛查52568例,纳入2164例(1508例男性[70%],平均[SD]年龄46[19]岁,损伤严重度评分中位数29[IQR 17-36])。
- 1498例(69.2%)接受去甲肾上腺素;24小时死亡率为17.8%(385/2164),院内死亡率为35.6%(770/2164)。
- 采用Rubin因果模型,以倾向评分逆概率加权及双重稳健方法共5种分析策略估计平均治疗效应;5种策略均未显示去甲肾上腺素与24小时死亡率存在统计学显著关联,ATE范围-4.6(95%CI -11.9至2.7)至2.1(95%CI -2.1至6.3)。
- 5种策略均未显示去甲肾上腺素与院内死亡率存在统计学显著关联,ATE范围-1.3(95%CI -9.5至6.9)至5.3(95%CI -2.1至12.8)。
证据类型、等级与局限
- 证据类型:回顾性、多中心、观察性队列研究。
- 作者结论:研究结果提示早期去甲肾上腺素输注与钝性创伤失血性休克患者的24小时或院内死亡率无关。
- 作者指出需随机临床试验研究早期去甲肾上腺素对创伤低血压患者的作用,以进一步评估去甲肾上腺素对失血性休克患者是否安全。
对床旁实践的改变
- 研究结果提示,钝性创伤失血性休克患者出血控制前早期持续去甲肾上腺素与24小时及院内死亡率无统计学显著关联;作者认为需随机临床试验进一步评估其安全性。
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Hemorrhagic shock is a common cause of preventable death after injury. Vasopressor administration for patients with blunt trauma and hemorrhagic shock is often discouraged.
OBJECTIVE: To evaluate the association of early norepinephrine administration with 24-hour mortality among patients with blunt trauma and hemorrhagic shock.
DESIGN, SETTING, AND PARTICIPANTS: This retrospective, multicenter, observational cohort study used data from 3 registries in the US and France on all consecutive patients with blunt trauma from January 1, 2013, to December 31, 2018. Patients were alive on admission with hemorrhagic shock, defined by prehospital or admission systolic blood pressure less than 100 mm Hg and evidence of hemorrhage (ie, prehospital or resuscitation room transfusion of packed red blood cells, receipt of emergency treatment for hemorrhage control, transfusion of >10 units of packed red blood cells in the first 24 hours, or death from hemorrhage). Blunt trauma was defined as any exposure to nonpenetrating kinetic energy, collision, or deceleration. Statistical analysis was performed from January 15, 2021, to February 22, 2022.
EXPOSURE: Continuous administration of norepinephrine in the prehospital environment or resuscitation room prior to hemorrhage control, according to European guidelines.
MAIN OUTCOMES AND MEASURES: The primary outcome was 24-hour mortality, and the secondary outcome was in-hospital mortality. The average treatment effect (ATE) of early norepinephrine administration on 24-hour mortality was estimated according to the Rubin causal model. Inverse propensity score weighting and the doubly robust approach with 5 distinct analytical strategies were used to determine the ATE.
RESULTS: A total of 52 568 patients were screened for inclusion, and 2164 patients (1508 men [70%]; mean [SD] age, 46 [19] years; median Injury Severity Score, 29 [IQR, 17-36]) presented with acute hemorrhage and were included. A total of 1497 patients (69.1%) required emergency hemorrhage control, 128 (5.9%) received a prehospital transfusion of packed red blood cells, and 543 (25.0%) received a massive transfusion. Norepinephrine was administered to 1498 patients (69.2%). The 24-hour mortality rate was 17.8% (385 of 2164), and the in-hospital mortality rate was 35.6% (770 of 2164). None of the 5 analytical strategies suggested any statistically significant association between norepinephrine administration and 24-hour mortality, with ATEs ranging from -4.6 (95% CI, -11.9 to 2.7) to 2.1 (95% CI, -2.1 to 6.3), or between norepinephrine administration and in-hospital mortality, with ATEs ranging from -1.3 (95% CI, -9.5 to 6.9) to 5.3 (95% CI, -2.1 to 12.8).
CONCLUSIONS AND RELEVANCE: The findings of this study suggest that early norepinephrine infusion was not associated with 24-hour or in-hospital mortality among patients with blunt trauma and hemorrhagic shock. Randomized clinical trials that study the effect of early norepinephrine administration among patients with trauma and hypotension are warranted to further assess whether norepinephrine is safe for patients with hemorrhagic shock.
参考来源
- Gauss T, Richards JE, Tortù C, et al. Association of Early Norepinephrine Administration With 24-Hour Mortality Among Patients With Blunt Trauma and Hemorrhagic Shock. JAMA Netw Open. 2022. PMID: 36205999. doi:10.1001/jamanetworkopen.2022.34258
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。